Avutometinib potassium is used for the research of low-grade serous ovarian cancer (LGSOC), ovarian cancer, and pancreatic ductal adenocarcinoma (PDAC); it exhibits antiproliferative activity in KRAS-mutant tumor cell lines, including PDAC cell lines, and induces tumor suppression and improves survival in KRAS/p53 pancreatic cancer mouse models.